JPRN-jRCTs031260239 [18F]FAPI-74 Idiopathic Inflammatory Myopathies Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook

Turn a newly registered trial into a decision-ready landscape. This focused report examines JPRN-jRCTs031260239—[18F] Fibroblast Activation Protein Inhibitor PET/CT for Evaluation of Lung Fibrosis Activity in Connective Tissue Disease-Associated Interstitial Lung Disease (FALCON Study)—using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, Drug & Asset MCP for mechanism and development context, and Company & Deal Intelligence MCP for sponsor background. Explore PatSnap MCP Servers to reproduce the workflow inside an AI research process.

MCP evidence snapshot: 20 July 2026; publication date: 20 July 2026. Trial records can change after the snapshot and should be rechecked before operational decisions.

Why JPRN-jRCTs031260239 is a hot trial to watch

Idiopathic Inflammatory Myopathies is increasingly segmented by mechanism, biomarker, treatment setting, geography and endpoint architecture. JPRN-jRCTs031260239 is notable because it evaluates [18F]FAPI-74 in a Phase 2 design while 【FALCON cross sectional study】 %DLCO（Hb補正） 【FALCON prospective cohort study】 観察期間におけるPPFの発生 serves as the main decision variable. The critical question is whether the protocol can convert its rationale into a clinically interpretable and operationally credible readout.

PatSnap Clinical Trials MCP makes protocol fields machine-readable, while the companion asset and organization servers add development-status, target and sponsor context.

Trial landscape snapshot

Design and endpoint interpretation

The phase label is only the starting point. Allocation is Non-Randomized, masking is Open Label, and the intervention model is Single Group Assignment. Planned enrollment of 50 participants across Japan shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.

• Primary: 【FALCON cross sectional study】 %DLCO（Hb補正） 【FALCON prospective cohort study】 観察期間におけるPPFの発生
• Primary: [FALCON cross sectional study] %DLCO (hemoglobin-corrected) [FALCON prospective cohort study] Occurrence of PPF during the observation period
• Secondary: 【FALCON cross sectional study】 - %FVC - 血清KL-6 - KL-6以外の血清バイオマーカー - 患者報告型アウトカム尺度（K-BILD、mMRC） - 関節リウマチ患者での疾患活動性（DAS28-CRP、手レントゲン） - HRCTにおけるTotal disease extent（%） 【FALCON prospective cohort study】 - 観察期間におけるProgressor（PPF基準を満たす、もしくはILDに対する治療強化）の発生 - 観察期間におけるPPF3項目中1項目以上の基準を満たす事象の発生 - 観察期間における%FVC・FVCの年換算変化量 - 観察期間における%DLCO（Hb補正）・DLCO（Hb補正）の年換算変化量 - 観察期間における血清KL-6の変化割合 - 観察期間における患者報告型アウトカム尺度（K-BILD、mMRC）の変化量
• Secondary: [FALCON cross sectional study] - %FVC - Serum KL-6 - Serum biomarkers other than KL-6 - Patient-reported outcome measures (K-BILD, mMRC) - Disease activity in patients with rheumatoid arthritis (DAS28-CRP, hand radiography) - Total disease extent on HRCT (%) [FALCON prospective cohort study] - Occurrence of progressor (defined as meeting PPF criteria or treatment intensification for ILD) during the observation period - Occurrence of events meeting at least one of the three PPF domains during the observation period - Annualized change in %FVC and FVC during the observation period - Annualized change in %DLCO (hemoglobin-corrected) and DLCO (hemoglobin-corrected) during the observation period - Percent change in serum KL-6 during the observation period - Change in patient-reported outcome measures (K-BILD, mMRC) during the observation period

Benchmark readouts in the surrounding field

• A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of RDX-002 on Postprandial Triglycerides in Patients Discontinuing the Glucagon-like Peptide-1 (GLP-1) Agonists, Semaglutide, or Tirzepatide for the Treatment of Obesity (Phase 2): Incremental Postprandial Triglycerides (TG)(Mean) = 43.81 percent change (Standard Deviation, 92.373); Incremental Postprandial Triglycerides (TG)(Mean) = -51.91 percent change (Standard Deviation, 72.293)
• A Phase II Study to Evaluate the Delay in Ovulation Following Oral Levonorgestrel Plus Meloxicam Compared to Placebo in Obese But Normal Menstruating Women (Phase 2): Interval From First Dose to Evidence of Ovulation.(Mean) = 2.67 Number of days (Standard Deviation, 1.53); Interval From First Dose to Evidence of Ovulation.(Mean) = 4.0 Number of days (Standard Deviation, 0)
• A Phase 2, Parallel-Group, Double-Blind Study to Investigate Weight Management With LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight (Phase 2): Percent Change From Baseline in Body Weight at Week 48(Least Squares Mean) = -0.4 percent change (Standard Error, 0.91); Percent Change From Baseline in Body Weight at Week 48(Least Squares Mean) = -9.4 percent change (Standard Error, 1.60)

These indexed results are contextual benchmarks, not direct head-to-head evidence. Population, treatment line, endpoint definitions, follow-up and analysis sets may differ. Their value is to clarify the type and magnitude of evidence already visible in the competitive landscape.

Build a living trial monitor: connect to PatSnap MCP Servers and track status changes, endpoint revisions, primary-completion dates and newly indexed results without manually reconciling separate databases.

Asset and sponsor context

Drug & Asset context: [18F]FAPI-74 (Phase 3; FAP); 18F-FAPI (Phase 2/3; target not reported)

Company & Deal Intelligence context: Not reported

The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can decide whether a positive signal becomes a competitive asset.

White space around this program

• Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
• Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
• Sequencing evidence: comparative data after the most relevant contemporary standard of care.
• Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
• Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.

What to monitor next

Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter probability of success before a headline data release.

Bottom line

JPRN-jRCTs031260239 is a focused lens on Idiopathic Inflammatory Myopathies development. Its value will be determined by whether [18F]FAPI-74 can convert the current design into evidence that is clinically meaningful, operationally credible and differentiated from indexed benchmark readouts.

Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.